Gerald McMahon
- Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism 16
- Carcinogens and Genotoxicity Assessment 6
- Immunology and Allergy top 0.5%
- Oncology top 0.5%
- HER2/EGFR in Cancer Research 6
- Molecular Biology top 0.5%
- Angiogenesis and VEGF in Cancer 25
- PI3K/AKT/mTOR signaling in cancer 8
- DNA Repair Mechanisms 5
- Hematology top 1%
-
- Bioactive Compounds and Antitumor Agents 6
-
- Mast cells and histamine 6
Gerald McMahon
77 papers receiving 11.4k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Cancer Research 2.9k
- Immunology and Allergy 765
- Oncology 3.1k
- Molecular Biology 7.0k
- Hematology 946
Countries citing papers authored by Gerald McMahon
This map shows the geographic impact of Gerald McMahon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald McMahon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald McMahon more than expected).
Fields of papers citing papers by Gerald McMahon
This network shows the impact of papers produced by Gerald McMahon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald McMahon. The network helps show where Gerald McMahon may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gerald McMahon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 29 | |
| 2 | 2016 | 3 | |
| 3 | 2015 | 4 | |
| 4 | 2010 | 44 | |
| 5 | 2005 | 311 | |
| 6 | 2004 | 68 | |
| 7 | 2004 | 48 | |
| 8 | Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. | 2003 | 220 |
| 9 | 2003 | 33 | |
| 10 | 2003 | 19 | |
| 11 | 2003 | 51 | |
| 12 | 2001 | 28 | |
| 13 | Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. | 2001 | 281 |
| 14 | 2000 | 268 | |
| 15 | Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesisbreakdown → | 2000 | 2218 |
| 16 | 1998 | 28 | |
| 17 | 1996 | 46 | |
| 18 | Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoidsbreakdown → | 1995 | 598 |
| 19 | 1995 | 19 | |
| 20 | 1994 | 10 |
About Gerald McMahon
Gerald McMahon is a scholar working on Toxicology, Cancer Research, Molecular Biology, Oncology and Genetics, having authored 77 papers that have together received 11.8k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (25 papers), Cancer, Hypoxia, and Metabolism (16 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Bioactive Compounds and Antitumor Agents (6 papers), HER2/EGFR in Cancer Research (6 papers), Carcinogens and Genotoxicity Assessment (6 papers), Mast cells and histamine (6 papers) and DNA Repair Mechanisms (5 papers). The work is most often cited by research in Cancer Research (2.9k citations), Immunology and Allergy (765 citations), Oncology (3.1k citations), Molecular Biology (7.0k citations) and Hematology (946 citations). Gerald McMahon has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Cho Tang, Li Sun, Gabriele Bergers, Douglas Hanahan, Zena Werb, Takeshi Itoh, Thiennu H. Vu, Kazuhiko Tamaki, Philip E. Thorpe and Shigeyoshi Itohara. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Medicinal Chemistry, Blood, Archives of Biochemistry and Biophysics and Cancer Biology & Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.